The Cancer Prevention and Control Program (CPCP) is a productive and interactive multi-disciplinary team of 19 investigators, including 17 Full and two Associate Qunior mentored) Members drawn from 7 academic departments. The goal of the CPCP is to conduct innovative and high impact research in childhood cancer prevention and control through an integrated program encompassing outcomes and intervention research. Using institutional and national CPCP-led research resources consisting of the St. Jude Lifetime (SJLIFE) cohort, the Childhood Cancer Survivor Study (CCSS) cohort, and the St. Jude Consortium for Pediatric Intervention Research (CPIR), program members are conducting cancer survivorship-based research to describe the occurrence and pathogenesis of physiological and psychological long-term outcomes associated with the diagnosis and treatment of cancer during childhood and adolescence. A central theme of the CPCP is to translate findings from clinical and observational research into clinical practice or intervention trials designed to prevent or ameliorate the acute and long-term morbidity of treatment and improve quality of life. To. this end, the Program is organized around three principal areas of Research Emphasis: (1) Identification of High-Risk Groups and Insights into the Mechanisms of Treatment-related Outcomes. (2) Translation of Observational Research into Clinical Practice. (3) Translation of Observational Research into Intervention Trials Insights The CPCP relies heavily upon the Cancer Center's Biostatistics, Molecular Therapeutic Clinical Trials, and Hartwell Center shared resources. CPCP members are actively engaged in numerous protocol-specific collaborations with other Cancer Center programs. The CPCP membership is supported by $8.0 million in cancer-related funding ($7.9 million peer-reviewed; $0.1 million non-peer reviewed) and has published 406 papers of which 27% (n=110/406) were intraprogrammatic and 26% (n=104/406) were interprogrammatic.
Almost 80% of U.S. children with cancer now survive beyond 5 years from diagnosis. These improved outcomes have resulted in a growing population of childhood cancer survivors, now estimated to number more than 370,000. This population is at increased risk for a variety of health problems. CPCP investigators are conducting research to further define the occurrence of, and risk factors for; these adverse late outcomes in order to develop intervention approaches that improve the quality of life of childhood cancer survivors.
|ElInati, Elias; Russell, Helen R; Ojarikre, Obah A et al. (2017) DNA damage response protein TOPBP1 regulates X chromosome silencing in the mammalian germ line. Proc Natl Acad Sci U S A 114:12536-12541|
|Gibson, Todd M; Li, Zhenghong; Green, Daniel M et al. (2017) Blood Pressure Status in Adult Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 26:1705-1713|
|Scott, Daniel C; Hammill, Jared T; Min, Jaeki et al. (2017) Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase. Nat Chem Biol 13:850-857|
|Patel, Y T; Daryani, V M; Patel, P et al. (2017) Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas. CPT Pharmacometrics Syst Pharmacol 6:305-314|
|Penkert, Rhiannon R; Jones, Bart G; Häcker, Hans et al. (2017) Vitamin A differentially regulates cytokine expression in respiratory epithelial and macrophage cell lines. Cytokine 91:1-5|
|Howell, Carrie R; Wilson, Carmen L; Ehrhardt, Matthew J et al. (2017) Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study. Cancer :|
|Talleur, Aimee C; Triplett, Brandon M; Federico, Sara et al. (2017) Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Hapl Biol Blood Marrow Transplant 23:1910-1917|
|Wu, Jianrong (2017) Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model. Stat Biopharm Res 9:25-34|
|Svolos, P; Reddick, W E; Edwards, A et al. (2017) Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation. AJNR Am J Neuroradiol 38:1235-1241|
|Lin, Wenwei; Goktug, Asli N; Wu, Jing et al. (2017) High-Throughput Screening Identifies 1,4,5-Substituted 1,2,3-Triazole Analogs as Potent and Specific Antagonists of Pregnane X Receptor. Assay Drug Dev Technol 15:383-394|
Showing the most recent 10 out of 6607 publications